Moderna retreats 8% amid valuation debate ahead of cancer data (MRNA:NASDAQ)
· seekingalpha.com
Moderna (MRNA) slides 8% after a 64% rally as analysts debate valuation ahead of Oct. 24 cancer-vaccine data.
On the Move Moderna retreats 8% amid valuation debate ahead of cancer data Oct 16, 2026, 4:46 PM ET Moderna, Inc. (MRNA) Stock By : SA News, SA News Editor AI-g...